Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae:: data from the global PROTEKT surveillance programme

被引:98
|
作者
Canton, R
Morosini, M
Enright, MC
Morrissey, I
机构
[1] GR Micro Ltd, London NW1 3ER, England
[2] Univ Bath, Bath BA2 7AY, Avon, England
[3] Hosp Ramon & Cajal, E-28034 Madrid, Spain
关键词
multilocus sequence typing; Spain(23F)-1; topoisomerase mutations; fluoroquinolone resistance;
D O I
10.1093/jac/dkg465
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To analyse the mutations and epidemiology associated with fluoroquinolone-resistant pneumococci collected as part of the PROTEKT global surveillance programme during 1999-2000. Methods: Sixty-nine centres in 25 countries submitted a total of 3362 Streptococcus pneumoniae isolates, for which the MICs of antimicrobial agents were determined using NCCLS methodology. Results: Levofloxacin resistance was low overall (1% worldwide), with higher rates in: Hong Kong (14.3%), South Korea (2.9%), USA (1.8%), Mexico (1.5%), Canada (1.4%) and Japan (1.3%). Levofloxacin resistance was very low or absent in European countries, and absent in Australia. Worldwide, there was a total of 35 levofloxacin-resistant isolates, of which 22 (63%) were resistant and 10 (29%) were intermediate to moxifloxacin. All levofloxacin-resistant isolates were susceptible to telithromycin (less than or equal to0.5 mg/L), linezolid (less than or equal to2 mg/L) and quinupristin/dalfopristin (less than or equal to1 mg/L). One or more mutations in the topoisomerase genes were identified in all levofloxacin-resistant isolates; most of these isolates (33/35) had a mutation in one of the DNA gyrase encoding genes (gyrA, gyrB) and one of the topoisomerase IV encoding genes (parC, parE). Eighteen (51%) isolates carried the same combination of amino acid substitutions: Ser-81-->Phe in GyrA and Ser-79-->Phe in ParC. Isolates displaying a levofloxacin MIC of 2-4 mg/L generally had no mutation or one mutation in either a DNA gyrase or a topoisomerase IV gene, although most mutations were in parC. Conclusions: Most levofloxacin-resistant isolates possess two mutations (one in DNA gyrase and one in topoisomerase IV). Although multilocus sequence typing demonstrated that most of these isolates were unrelated, 12 (34%) were the Spain(23F)-1 clone: 10 from Hong Kong and one each from Saskatchewan, Canada and Sao Paulo, Brazil.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 42 条
  • [1] Molecular characterization of clinical and laboratory fluoroquinolone-resistant Streptococcus pneumoniae
    Noreddin, AM
    Smith, HJ
    Nichol, KA
    Walkty, AM
    Hoban, DJ
    Zhanel, GG
    PHARMACOTHERAPY, 2003, 23 (03): : 409 - 409
  • [2] Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy:: report from the SENTRY Antimicrobial Surveillance Program (2001-2004)
    Deshpande, LM
    Sader, HS
    Debbia, E
    Nicoletti, G
    Fadda, G
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (03) : 157 - 164
  • [3] Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong
    Morrissey, I
    Farrell, DJ
    Bakker, S
    Buckridge, S
    Felmingham, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1433 - 1435
  • [4] Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin
    Marrer, E
    Satoh, AT
    Johnson, MM
    Piddock, LJV
    Page, MGP
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 269 - 278
  • [5] Fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Russia:: molecular mechanisms implicated
    Vereshchagin, VA
    Ilina, EN
    Malakhova, MV
    Zubkov, MM
    Sidorenko, SV
    Kubanova, AA
    Govorun, VM
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) : 653 - 656
  • [6] An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae
    Alonso, R
    Galimand, M
    Courvalin, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) : 682 - 683
  • [7] Molecular epidemiology of extended-spectrum β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan
    Yu, WL
    Jones, RN
    Hollis, RJ
    Messer, SA
    Biedenbach, DJ
    Deshpande, LM
    Pfaller, AA
    JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) : 4666 - 4669
  • [8] Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence
    Fukushima, Kazuko Y.
    Hirakata, Yoichi
    Sugahara, Kazuyuki
    Yanagihara, Katsunori
    Kondo, Akira
    Kohno, Shigeru
    Kamihira, Shimeru
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (12) : 4553 - 4558
  • [9] Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and β-lactams:: SMART program 2001 data
    Hsueh, PR
    Teng, LJ
    Wu, TL
    Yang, D
    Huang, WK
    Shyr, JM
    Chuang, YC
    Wan, JH
    Yan, JJ
    Lu, JJ
    Wu, JJ
    Ko, WC
    Chang, FY
    Yan, YC
    Lau, YJ
    Liu, YC
    Lee, CM
    Leu, HS
    Liu, CY
    Luh, KT
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2145 - 2151
  • [10] Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada
    Hoban, DJ
    Zhanel, GG
    Walkty, A
    Nichol, K
    Smith, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 : 32 - 32